1.45
+0.12(+9.02%)
Currency In USD
| Previous Close | 1.33 |
| Open | 1.32 |
| Day High | 1.45 |
| Day Low | 1.32 |
| 52-Week High | 2.5 |
| 52-Week Low | 1.29 |
| Volume | 119,472 |
| Average Volume | 72,749 |
| Market Cap | 52.1M |
| PE | -0.68 |
| EPS | -2.12 |
| Moving Average 50 Days | 1.77 |
| Moving Average 200 Days | 1.8 |
| Change | 0.12 |
If you invested $1000 in Rafael Holdings, Inc. (RFL) since IPO date, it would be worth $295.92 as of May 12, 2025 at a share price of $1.45. Whereas If you bought $1000 worth of Rafael Holdings, Inc. (RFL) shares 5 years ago, it would be worth $114.35 as of May 12, 2025 at a share price of $1.45.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Rafael Holdings, Inc. Announces Revised Subscription Rights in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™
GlobeNewswire Inc.
May 05, 2025 11:00 AM GMT
NEWARK, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) today announced revised subscription rights in connection with its previously announced rights offering. Holders of record as of May 9, 2025 (th
Rafael Holdings, Inc. Announces Proposed Terms of a $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™
GlobeNewswire Inc.
Apr 29, 2025 8:30 PM GMT
NEWARK, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL; NYSE American: RFL-WT) today announced a rights offering, including key dates and terms. The planned offering is designed to provide existing stockholders and holder
Rafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role
GlobeNewswire Inc.
Apr 24, 2025 8:15 PM GMT
Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the mid